Search - tctmd.com

Displaying 321 - 340 of 802

Sort: Relevancy | Date

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

TAVR in Bicuspid Aortic Valves: Insights From BIVOLUT-X

Michael O'Riordan

November 22, 2019

News Conference News PCR London Valves 2019

Solid 2-Year Outcomes for Portico, With Paravalvular Leak Rare

Michael O'Riordan

November 20, 2019

News Conference News PCR London Valves 2019

Signal of Impaired Sapien XT Durability in Midterm Follow-up

Michael O'Riordan

November 20, 2019

News Conference News AHA 2019

TAVR Valve Face-off: Two French Observational Studies Suggest Inherent Differences

Yael L. Maxwell

November 18, 2019

News Daily News

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Michael O'Riordan

November 06, 2019

Presentation Cardiovascular Interventions 2019

Show me the Data: Key Clinical Trials of 2019

Presenter: Ehtisham Mahmud

November 01, 2019

News Daily News

Interventional Options and Future Directions for Acute PE: New AHA Statement

Todd Neale

October 07, 2019

News Conference News TCT 2019

Predicting Final Valve Position After TAVR: Different Devices, Different Success

Michael O'Riordan

October 07, 2019

News Conference News TCT 2019

Watchman Adverse Events: Analysis Digs Into What’s Been Reported to the FDA

Todd Neale

October 04, 2019

News Conference News TCT 2019

TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3

Yael L. Maxwell

September 29, 2019

Presentation TCT 2019

The (R)evolution of Image-based FFR – Introducing the CathWorks FFRangio System

Presenter: Bruce Samuels

September 27, 2019

Presentation TCT 2019

Keynote Lecture: A Vision for an Evolving Regulatory and Healthcare System

Presenter: Robert Califf

September 26, 2019

Presentation TCT 2019

WATCHMAN: Device Characteristics, Procedural Technique, Clinical Outcomes, Ongoing Studies, and Evolution to WATCHMAN FLX

Presenter: Saibal Kar

September 26, 2019

Presentation TCT 2019

Keynote Lecture: New Technology Assessment and Reimbursement Synergy — Forward Strides

Presenter: Lori Ashby

September 26, 2019

Presentation TCT 2019

Deep-Dive: NEW Insights From the Evolut Low-Risk Trial

Presenter: Michael Reardon

September 26, 2019

Presentation TCT 2019

Keynote Lecture: FDA/CDRH — The Year in Review, Focus on CDRH’s Total Product Life Cycle Concept

Presenter: William Maisel

September 26, 2019

News Conference News TCT 2019

Personalized CT-Derived Modeling Guides Choices in Bicuspid Aortic Valve Disease

Michael O'Riordan

September 25, 2019

Presentation TCT 2019

COAPT, Partner 2, and Evolut Low-Risk Trial Synopsis and What They Mean Moving Forward

Presenter: Elizabeth Perpetua

September 25, 2019

Presentation TCT 2019

The Technology Evolut™ System: Overview and Performance

Presenter: Michael Caskey

September 25, 2019

Advertisement

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

TAVR in Bicuspid Aortic Valves: Insights From BIVOLUT-X

Solid 2-Year Outcomes for Portico, With Paravalvular Leak Rare

Signal of Impaired Sapien XT Durability in Midterm Follow-up

TAVR Valve Face-off: Two French Observational Studies Suggest Inherent Differences

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Show me the Data: Key Clinical Trials of 2019

Interventional Options and Future Directions for Acute PE: New AHA Statement

Predicting Final Valve Position After TAVR: Different Devices, Different Success

Watchman Adverse Events: Analysis Digs Into What’s Been Reported to the FDA

TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3

The (R)evolution of Image-based FFR – Introducing the CathWorks FFRangio System

Keynote Lecture: A Vision for an Evolving Regulatory and Healthcare System

WATCHMAN: Device Characteristics, Procedural Technique, Clinical Outcomes, Ongoing Studies, and Evolution to WATCHMAN FLX

Keynote Lecture: New Technology Assessment and Reimbursement Synergy — Forward Strides

Deep-Dive: NEW Insights From the Evolut Low-Risk Trial

Keynote Lecture: FDA/CDRH — The Year in Review, Focus on CDRH’s Total Product Life Cycle Concept

Personalized CT-Derived Modeling Guides Choices in Bicuspid Aortic Valve Disease

COAPT, Partner 2, and Evolut Low-Risk Trial Synopsis and What They Mean Moving Forward

The Technology Evolut™ System: Overview and Performance

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content